Back to top

Image: Bigstock

Here's What Key Metrics Tell Us About CVRx (CVRX) Q3 Earnings

Read MoreHide Full Article

CVRx (CVRX - Free Report) reported $13.83 million in revenue for the quarter ended September 2026, representing a year-over-year decline of 5.8%. EPS of -$0.52 for the same period compares to -$0.49 a year ago.

The reported revenue represents a surprise of -0.94% over the Zacks Consensus Estimate of $13.96 million. With the consensus EPS estimate being -$0.49, the EPS surprise was -6.12%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how CVRx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
  • Active Implanting Centers: 262 compared to the 263 average estimate based on two analysts.
  • U.S. Revenue Units: 412 versus the two-analyst average estimate of 413.
  • Number of Sales Territories in the U.S.: 56 versus the two-analyst average estimate of 56.
  • Geographic Revenue- Europe: $0.9 million versus $1 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -25% change.
  • Geographic Revenue- United States: $13 million versus the two-analyst average estimate of $12.85 million. The reported number represents a year-over-year change of -3.7%.

View all Key Company Metrics for CVRx here>>>

Shares of CVRx have returned -5.4% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Published in